EUVIMEDSkopri EUVIMED
Crossref

Roflumilast Foam (Zoryve) for Seborrheic Dermatitis

The Medical Letter on Drugs and Therapeutics · 2024

DOI: 10.58347/tml.2024.1700a ↗

At a glance

Journal article in The Medical Letter on Drugs and Therapeutics, 2024. Major MEDLINE topics: Dermatitis, Seborrheic, Dermatologic Agents. Cited 2 times so far (Crossref).

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

The FDA has approved a 0.3% foam formulation of the phosphodiesterase-4 (PDE4) inhibitor roflumilast (Zoryve – Arcutis) for topical treatment of seborrheic dermatitis in patients ≥9 years old. Roflumilast is the first PDE4 inhibitor to be approved in the US for this indication.

Subjects

MeSH terms (MEDLINE)

Dermatitis, SeborrheicDermatologic AgentsHumansAminopyridinesBenzamidesCyclopropanesTreatment OutcomeAdministration, Topical

Author keywords

DalirespElidelProtopicZoryveadverse effectsantifungalsbetamethasoneciclopiroxcorticosteroidsdosagedrug interactionsefficacyhydrocortisoneketoconazolelactation

Substances

RoflumilastAminopyridinesBenzamidesCyclopropanesDermatologic Agents

Cite

APA

(2024). Roflumilast Foam (Zoryve) for Seborrheic Dermatitis. The Medical Letter on Drugs and Therapeutics. https://doi.org/10.58347/tml.2024.1700a

Vancouver

Roflumilast Foam (Zoryve) for Seborrheic Dermatitis. The Medical Letter on Drugs and Therapeutics. 2024. doi:10.58347/tml.2024.1700a

BibTeX
@article{euvimed2024,
  title = {Roflumilast Foam (Zoryve) for Seborrheic Dermatitis},
  journal = {The Medical Letter on Drugs and Therapeutics},
  year = {2024},
  doi = {10.58347/tml.2024.1700a}
}
Start for free →